Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents
Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after…
Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after…
For any drug developer or service provider, cell line development is one of the most challenging phases, especially…
Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a…
AstraZeneca's MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a…
The new Biotech Nodthera will be based in Edinburgh and focus on the discovery and development of…
What is the purpose of the #NoHep campaign? To get rid of the inflammatory Liver…
Here are 3 events to kickstart your greentech career. As Europe works towards a bioeconomy, challenges like…
Since the days of the Soviet Union, Lithuania has always been considered as a leader…
A new study has shown that on average, 70% of eczema patients are colonised with Staphylococcus…
InflaRx, a German-based biopharma, has raised €31M in a series C fundraising. This is to further…
Researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have uncovered a molecule in the pomegranate fruit…
Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious…